Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 32938569

Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Eur Urol
Publication date
2020 Dec
First author
Pal SK

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Pal SK
      type
      Author
    2. name
      Escudier BJ
      type
      Author
    3. name
      Atkins MB
      type
      Author
    4. name
      Hutson TE
      type
      Author
    5. name
      Porta C
      type
      Author
    6. name
      Verzoni E
      type
      Author
    7. name
      Needle MN
      type
      Author
    8. name
      Powers D
      type
      Author
    9. name
      McDermott DF
      type
      Author
    10. name
      Rini BI
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Pal SK
      type
      Author
    2. name
      Escudier BJ
      type
      Author
    3. name
      Atkins MB
      type
      Author
    4. name
      Hutson TE
      type
      Author
    5. name
      Porta C
      type
      Author
    6. name
      Verzoni E
      type
      Author
    7. name
      Needle MN
      type
      Author
    8. name
      Powers D
      type
      Author
    9. name
      McDermott DF
      type
      Author
    10. name
      Rini BI
      type
      Author
    bibliography ids
    1. nci-bib-f2f00de3f774555430c4ebb0
    book metadata
    content sha256
    bae66b8dda4b152e981f1fd926511bba83d682834b76f07555f24d7ae7431690
    document type
    citation
    dois
    1. 10.1016/j.eururo.2020.08.007
    electronic publication date
    display
    2020 Sep 13
    precision
    day
    year
    2020
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:32938569
    immutable id
    pubmed:32938569@bae66b8dda4b152e981f1fd926511bba83d682834b76f07555f24d7ae7431690
    journal
    abbreviation
    Eur Urol
    issn electronic
    1873-7560
    issn print
    0302-2838
    issue
    6
    name
    European urology
    nlm unique id
    7512719
    pages
    783-785
    volume
    78
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      32938569
      provenance
      batch id
      9bca82d1bba2b27adc79
      provider
      NCBI PubMed ESummary
      record sha256
      e4d6936468e04f799db119ace236ea53cdfc181d59d174bc83b20d29fa399f83
      response sha256
      c8a4853c65a45038af15f5ade3970763bfa121cf5c68bafcc52c3a06860d0211
      retrieved at
      2026-09-09T23:47:56.131551+00:00
      publication date
      display
      2020 Dec
      precision
      month
      year
      2020
      publication types
      1. Clinical Trial, Phase III
      2. Comparative Study
      3. Journal Article
      4. Randomized Controlled Trial
      5. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/32938569/
      title
      Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma.

      Preserved source evidence · Not medical advice